Natalizumab in the treatment of pediatric multiple sclerosis

被引：0

作者：

Talab, Radomir ^{[1
]}

Talabova, Marika ^{[1
]}

Klzo, Ludovit ^{[2
]}

机构：

[1] Univ Hosp Hradec Kralove, Dept Neurol, MS Ctr, Hradec Kralove 50002, Czech Republic

[2] Univ Hosp Hradec Kralove, Dept Radiodiagnost, Hradec Kralove 50002, Czech Republic

来源：

NEUROENDOCRINOLOGY LETTERS | 2012年 / 33卷 / 06期

关键词：

pediatric multiple sclerosis; relapse; EDSS; natalizumab; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; CNS INFLAMMATORY DEMYELINATION; HEPATITIS-B-VACCINE; RISK; CHILDHOOD; INTERFERON; ONSET;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pediatric cerebrospinal multiple sclerosis (MS) constitutes about 2-5% of all MS cases. The International Pediatric MS Study Group (IPMSSG) applies diagnostic criteria for adults to MS in childhood and adolescence. Recent publications highlight an increasing number of MS in children resistant to the first-line treatment, i.e. disease modifying therapy (DMT). Furthermore, the number of published case studies on children with highly active MS treated with natalizumab also rises, whereas long-term risks as well as therapeutic potential of this therapy in pediatric population have been at the centre of attention. This paper presents a group of 5 children in whom natalizumab was selected to manage highly active disease or resistance to conventional MS treatment and provided very good clinical as well as MRI results.

引用

页码：579 / 589

页数：11

共 23 条

[1]

Ann Yeh E, 2010, THER ADV NEUROL DISO, V3, P293

[2] Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis [J].

Banwell, B ;

Reder, AT ;

Krupp, L ;

Tenembaum, S ;

Eraksoy, M ;

Alexey, B ;

Pohl, D ;

Freedman, M ;

Schelensky, L ;

Antonijevic, I .

NEUROLOGY, 2006, 66 (04) :472-476

[3]

Bauer HJ, 1989, AKTUELLE NEUROPEDIAT, P285

[4] Natalizumab treatment in pediatric multiple sclerosis: A case report [J].

Borriello, Giovanna ;

Prosperini, Luca ;

Luchetti, Anna ;

Pozzilli, Carlo .

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2009, 13 (01) :67-71

[5] The incidence and significance of anti-natalizumab antibodies -: Results from AFFIRM and SENTINEL [J].

Calabresi, P. A. ;

Giovannoni, G. ;

Confavreux, C. ;

Galetta, S. L. ;

Havrdova, E. ;

Hutchinson, M. ;

Kappos, L. ;

Miller, D. H. ;

O'Connor, P. W. ;

Phillips, J. T. ;

Polman, C. H. ;

Radue, E. -W. ;

Rudick, R. A. ;

Stuart, W. H. ;

Lublin, F. D. ;

Wajgt, A. ;

Weinstock-Guttman, B. ;

Wynn, D. R. ;

Lynn, F. ;

Panzara, M. A. ;

Macdonell, R. ;

Hughes, A. ;

Taylor, I. ;

Lee, Y. C. ;

Ma, H. ;

King, J. ;

Kilpatrick, T. ;

Butzkueven, H. ;

Marriott, M. ;

Pollard, J. ;

Spring, P. ;

Spies, J. ;

Barnett, M. ;

Dehaene, I. ;

Vanopdenbosch, L. ;

D'Hooghe, M. ;

Van Zandijcke, M. ;

Derijck, O. ;

Seeldrayers, P. ;

Jacquy, J. ;

Piette, T. ;

De Cock, C. ;

Medaer, R. ;

Soors, P. ;

Vanroose, E. ;

Vanderhoven, L. ;

Nagels, G. ;

Dubois, B. ;

Deville, M. -C. ;

D'Haene, R. .

NEUROLOGY, 2007, 69 (14) :1391-1403

[6] Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience [J].

Ghezzi, Angelo ;

Amato, Maria Pia ;

Annovazzi, Pietro ;

Capobianco, Marco ;

Gallo, Paolo ;

La Mantia, Loredana ;

Marrosu, Maria Giovanna ;

Martinelli, Vittorio ;

Milani, Nicoletta ;

Moiola, Lucia ;

Patti, Francesco ;

Pozzilli, Carlo ;

Trojano, Maria ;

Zaffaroni, Mauro ;

Comi, Giancarlo .

NEUROLOGICAL SCIENCES, 2009, 30 (03) :193-199

[7]

Hanefeld FA, 1993, MULTIPLE SCLEROSIS I, P14

[8]

Havrdova E, 2007, REMEDIA, V17, P61

[9]

Havrdova E, 2010, REMEDIA, V20, P278

[10] Natalizumab Use in Pediatric Multiple Sclerosis [J].

Huppke, Peter ;

Stark, Wiebke ;

Zuercher, Claudia ;

Huppke, Brenda ;

Brueck, Wolfgang ;

Gaertner, Jutta .

ARCHIVES OF NEUROLOGY, 2008, 65 (12) :1655-1658

← 1 2 3 →